Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study

Current Medical Research and Opinion

Volumn 32, Issue 11, 2016, Pages 1789-1795

  Sommerwerck, Urte ^a,b   Virella Lowell, Isabel ^c   Angyalosi, Gerhild ^d   Viegas, Andrea ^d   Cao, Weihua ^d   Debonnett, Laurie ^d  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Christiane Herzog Center Ruhr   (Germany)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cystic fibrosis; Dry powder inhaler (DPI); Pseudomonas aeruginosa; Safety; Tobramycin

Indexed keywords

CREATININE; TOBRAMYCIN; ANTIINFECTIVE AGENT; POWDER;

ADULT; ARTICLE; CHILD; COUGHING; CYSTIC FIBROSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY POWDER INHALER; DYSPNEA; FATIGUE; FEMALE; FEVER; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HEARING IMPAIRMENT; HEMOPTYSIS; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OROPHARYNX PAIN; PATIENT SATISFACTION; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RHINOPHARYNGITIS; SIDE EFFECT; THORAX PAIN; TINNITUS; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; INHALATIONAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; POWDER; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; COUGH; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; POWDERS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN;

EID: 84986223731     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2016.1211516     Document Type: Article

References (15)

1. P.A.Flume, P.J.MogayzelJr, K.A.Robinson,. Cystic fibrosis pulmonary guidelines:treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-8
2. L.Saiman, J.Siegel, J.LiPuma,. Infection prevention and control guideline for cystic fibrosis:2013 update. Infect Control Hosp Epidemiol 2014;35:S1-S67
3. J.M.Bhatt Treatment of pulmonary exacerbations in cystic fibrosis. Eur Respir Rev 2013;22:205-16
4. P.J.MogayzelJr, E.T.Naureckas, K.A.Robinson,. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187:680-9
5. D.E.Geller, M.W.Konstan, J.Smith,. Novel tobramycin inhalation powder in cystic fibrosis subjects:pharmacokinetics and safety. Pediatr Pulmonol 2007;42:307-13
6. M.W.Konstan, P.A.Flume, M.Kappler,. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients:the EAGER trial. J Cyst Fibros 2011;10:54-61
7. R.J.Knudson, M.D.Lebowitz, C.J.Holberg,. Changes in the normal maximal expiratory flow–volume curve with growth and aging. Am Rev Respir Dis 1983;127:725-34
8. Council For Clinical Certification in Audiology and Speech-Language Pathology of the American Speech-Language-Hearing Association. Standards for the Certificate of Clinical Competence in Audiology, 2012. Available at:http://www.asha.org/Certification/2012-Audiology-Certification-Standards/[Last accessed 30 September 2014]
9. M.W.Konstan Long-term safety and efficacy of tobramycin inhalation powder in cystic fibrosis patients with P. aeruginosa:the edit trial and its two open-label extension studies. 27th North American Cystic Fibrosis Conference 2013, Salt Lake City, UT, USA, 2013
10. M.J.Harrison, M.McCarthy, C.Fleming,. Inhaled versus nebulised tobramycin:a real world comparison in adult cystic fibrosis (CF). J Cyst Fibros 2014;13:692-8
11. M.W.Konstan, D.E.Geller, P.Minic,. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis:the EVOLVE trial. Pediatr Pulmonol 2011;46:230-8
12. C.M.Oermann, G.Z.Retsch-Bogart, A.L.Quittner,. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010;45:1121-34
13. V.Thompson, M.Kloster, P.A.Flume,. Hemoptysis is associated with underlying disease severity and is an expected adverse event in cystic fibrosis clinical trials. Pediatr Pulmonol 2014;49:352-3
14. I.Galeva, M.W.Konstan, M.Higgins,. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis:the randomized EDIT trial. Curr Med Res Opin 2013;29:947-56
15. T.G.Liou, E.P.Elkin, D.J.Pasta,. Year-to-year changes in lung function in individuals with cystic fibrosis. J Cyst Fibros 2010;9:250-6